Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
344 GBX | -1.71% | +11.69% | +21.55% |
03:34pm | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
11:55am | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.55% | 3.75B | |
+30.93% | 682B | |
+30.35% | 586B | |
-3.49% | 364B | |
+18.17% | 327B | |
+4.07% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.22% | 165B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : HUTCHMED Limited - Special Call